Hippokration Hospital
- Address
- lock Available on a paid plan
Hippokration Hospital - Advanced Clinical Research Center
Hippokration Hospital operates as a comprehensive clinical research facility with extensive expertise across multiple therapeutic domains. The center demonstrates particular strength in investigating novel therapies for complex metabolic, cardiovascular, and autoimmune conditions, with a robust portfolio spanning rare diseases, inflammatory disorders, and chronic systemic conditions.
- Cardiovascular and cardiometabolic diseases including heart failure, chronic kidney disease, hypertension, and prevention of cardiovascular events
- Autoimmune and inflammatory disorders such as systemic lupus erythematosus, Sjögren's syndrome, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), and psoriatic arthritis
- Hematologic conditions including hemophilia A, sickle cell disease, paroxysmal nocturnal hemoglobinuria, and acute myeloid leukemia
- Rare and specialized conditions encompassing giant cell arteritis, systemic sclerosis, hypertrophic cardiomyopathy, and IgA nephropathy
The hospital's research infrastructure supports innovative therapeutic approaches including gene therapy, monoclonal antibodies, and targeted small molecule inhibitors. Clinical trial expertise extends from early-phase adaptive dose-ranging studies to large-scale Phase III cardiovascular outcomes trials. The center maintains particular focus on combination therapy strategies, precision medicine approaches, and long-term safety extension studies. Research activities encompass pediatric through adult populations, addressing both acute and chronic disease management with emphasis on disease modification and improved clinical outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 20 therapeutic areas and 15 of 186 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 183 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 37 by active trials.
- 1Novartis Pharma AG6active
lock +36 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG11trials
lock +25 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hippokration Hospital
lock Showing 1 of 128 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Randomized Trial Comparing Flecainide Acetate and Amiodarone Hydrochloride for Cardioversion of Paroxysmal Atrial Fibrillation in Coronary Artery Disease | Win Medica Pharmaceutical S.A. | Phase III | Not Recruiting | Apr 2023 | Jan 2026 |
IMP list
lock Showing 1 of 186 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 7 | Unknown | 2023-11-07 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.